GRCE NASDAQ
Princeton, NJ 08540
US
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Opaleye Management I | P-Purchase | 7,849 | $2.09 | 2026-09-29 |
| Opaleye Management I | P-Purchase | 5,318 | $2.10 | 2026-09-23 |
| Opaleye Management I | P-Purchase | 5,318 | $2.10 | 2026-09-23 |
| Opaleye Management I | P-Purchase | 9,771 | $2.10 | 2026-09-21 |
| Opaleye Management I | P-Purchase | 9,771 | $2.10 | 2026-09-21 |